文献速递支持与姑息治疗

肿瘤高血压:癌症患者高血压治疗范式的转变

Onco-Hypertension: Changing Paradigm of Treating Hypertension in Patients With Cancer.
PubMed 文献 · J Clin Oncol · 2022-11-04

肿瘤高血压是癌症患者中常被低估的复杂临床难题。多种抗肿瘤药物(如贝伐珠单抗、酪氨酸激酶抑制剂、顺铂、卡非佐米)可导致新发或加重的高血压,而高血压也是肾细胞癌等某些癌症的风险因素。未治疗的高血压在癌症治疗前后可能增加短期和长期心脏毒性(如心力衰竭)风险,并影响癌症和心血管死亡率。由于多种药物相互作用、依从性差、对癌症治疗副作用的药物不耐受、高血压的不稳定性、使用类固醇和促红细胞生成素等非肿瘤药物以及癌症治疗与高血压相关基因之间的药物遗传学相互作用,癌症患者高血压的高效早期管理常具挑战性。

要点

  • 多种抗肿瘤药物如贝伐珠单抗、酪氨酸激酶抑制剂、顺铂、卡非佐米可导致新发或加重的高血压。
  • 高血压是肾细胞癌等某些癌症的风险因素,两者存在双向关联。
  • 癌症治疗前后未治疗的高血压可能增加心脏毒性风险并影响死亡率。

核心结论

  • 肿瘤高血压是癌症患者中一个被低估但复杂的临床难题,需要精准医学管理。

研究设计与样本

  • 肿瘤学大查房系列文章,通过病例展示、诊断和管理挑战描述、相关文献综述以及作者建议的管理方法总结来帮助读者理解如何将关键研究结果应用于临床实践。

主要发现

  • 多种抗肿瘤药物如贝伐珠单抗、酪氨酸激酶抑制剂、顺铂和卡非佐米可导致新发或加重的高血压。
  • 高血压是肾细胞癌等某些癌症的风险因素。
  • 癌症治疗前后未治疗的高血压可能增加短期和长期心脏毒性(如心力衰竭)风险,并影响癌症和心血管死亡率。
  • 癌症患者高血压的高效早期管理常因多种药物相互作用、依从性差、对癌症治疗副作用的药物不耐受、高血压的不稳定性、使用类固醇和促红细胞生成素等非肿瘤药物以及癌症治疗与高血压相关基因之间的药物遗传学相互作用而具有挑战性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Hypertension (HTN) in patients with cancer remains an underestimated yet complex clinical conundrum to merit its own marker of Onco-Hypertension. A myriad of antineoplastic drugs from vascular endothelial growth factor (VEGF) inhibitor antibodies such as bevacizumab, tyrosine kinase inhibitors (TKIs), cisplatin, and carfilzomib cause new or worsening HTN, and HTN is also a risk factor for certain cancers such as renal cell carcinoma. Untreated HTN before and during cancer treatment potentially increases the short-term and long-term risk of cardiotoxicity, such as heart failure, and affects both cancer and cardiovascular mortality. However, efficient and early management of HTN in patients with cancer is often challenging because of multiple drug interactions, noncompliance, and intolerance of medications because of the side effects of cancer treatments, labile nature of HTN, use of non-neoplastic drugs such as steroids and erythropoietin, and pharmacogenetic interactions between cancer treatment and HTN-related genes. The Oncology Grand Rounds aim to examine the bidirectional association and challenges of managing HTN in patients with cancer and the necessity for precision medicine to manage it.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sahni G. Onco-Hypertension: Changing Paradigm of Treating Hypertension in Patients With Cancer. J Clin Oncol. 2022. PMID: 36332165. doi:10.1200/JCO.22.01875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。